Austin Regional Infusion Center

About the Infusion Center

In order to assist CATRAC Regional Hospitals, a partnership between TDEM, Travis County, the City of Austin, Austin Public Health, CommUnityCare, EMTF and CATRAC established a Regional Infusion Center (RIC) to administer COVID 19 Monoclonal Antibodies to outpatients referred from area Physicians, Clinics, Urgent Care Centers and Emergency Departments.

The goal of this project is to prevent hospitalizations/ER visits for select patients with COVID 19 infection. The antibody is particularly effective for high risk COVID positive patients with mild/moderate symptoms who are less than 10 days from onset of symptoms.


Who is Eligible?

The FDA has granted the emergency use of Bamlanivimab, Casirivimab, and Imdevimab, which are medications used for the treatment of COVID-19 in patients who meet the following criteria:

  • COVID-19 positive
  • Non-hospitalized adults and adolescents 12 years of age and older
  • Mild to moderate symptoms
  • Weigh 88 pounds or more (high BMI over 35 for adults or over the 85th percentile for a child’s age and gender based on the CDC growth charts)
  • Underlying health conditions (chronic kidney disease, diabetes, immunosuppressive disease, cardiovascular disease, hypertension, respiratory disease, or other)
  • High risk for developing severe COVID-19 symptoms


High risk is defined as patients who meet at least one of the following criteria:

  • COVID-19 positive
  • Have a body mass index (BMI) ≥35
  • Have chronic kidney disease
  • Have diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment
  • Are ≥65 years of age
  • Are ≥55 years of age AND have
    • cardiovascular disease, OR
    • hypertension, OR
    • chronic obstructive pulmonary disease/other chronic respiratory disease.


  • Are 12 – 17 years of age AND have
    • BMI ≥85th percentile for their age and gender based on CDC growth charts,, OR
    • sickle cell disease, OR
    • congenital or acquired heart disease, OR
    • neurodevelopmental disorders, for example, cerebral palsy, OR
    • Muscular dystrophy or SMA, OR
    • a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
    • asthma, reactive airway or other chronic respiratory disease that requires daily medication for control


Information and Resources

Bamlanivimab FDA Fact Sheet:

Casirivimab and Imdevimab FDA Fact Sheet:

Contact Information

Office Number: 512-861-3630

Fax: 512-861-3629